
NDRA Stock Forecast & Price Target
NDRA Analyst Ratings
Bulls say
ENDRA Life Sciences Inc. is developing the Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at visualizing tissue in a manner similar to MRI, but at a lower cost and at the point of patient care. The anticipated FDA approval within the next year, underpinned by a favorable net present value (NPV) analysis, suggests substantial potential for the stock's appreciation. This innovative technology has the capacity to provide earlier diagnoses and more accurate monitoring of chronic liver conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), addressing a significant unmet need in a market affecting over one billion individuals globally.
Bears say
ENDRA Life Sciences Inc. reported a net loss of $1.6 million in the latest quarter, resulting in an earnings per share (EPS) of $(2.10), which was worse than the previous estimate of $(1.95). The company also faced a recurring net loss of $1.2 million with an EPS of $(1.71), not aligning with the earlier expectations of $(2.27). The financial outlook is further challenged by various risks, including balance sheet and liquidity issues, potential failures in clinical trials or regulatory approvals, difficulties in commercialization and reimbursement, as well as competition and shifting macroeconomic conditions.
This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
NDRA Analyst Forecast & Price Prediction
Start investing in NDRA
Order type
Buy in
Order amount
Est. shares
0 shares